What's new? Log in Free sign up

Tectonic Therapeutic (TECX)

Company Profile

Company profile

Ticker

TECX

Exchange

Website

CEO

Dr. Alise S. Reicin M.D., Ph.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment ...

Former names

AVROBIO, Inc., AvroBio, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AVROBIO Australia Pty Ltd • AVROBIO Securities Corporation ...

TECX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

$185.03 mm in equity, sold $185.03 mm, 29 investors

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement

Tectonic Announces $185 Million Private Placement

Regulation FD Disclosure

Regulation FD Disclosure

Quarterly report

12 Nov 24

Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Latest ownership filings

View all

BML Investment Partners, L.P.

Deep Track Capital, LP

SPRINGER TIMOTHY A

Vida Ventures II, LLC

MCGUIRE TERRANCE

TIMOTHY A SPRINGER

Financial summary

Financial statements Chart TECX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	159.68 mm	159.68 mm	159.68 mm	159.68 mm	159.68 mm	159.68 mm
Cash burn (monthly)	8.68 mm	(no burn)	6.55 mm	4.45 mm	6.53 mm	4.49 mm
Cash used (since last report)	44.46 mm	n/a	33.54 mm	22.80 mm	33.48 mm	23.02 mm
Cash remaining	115.22 mm	n/a	126.14 mm	136.88 mm	126.20 mm	136.66 mm
Runway (months of cash)	13.3	n/a	19.3	30.8	19.3	30.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

TECX institutional ownership history Ownership history

54.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	73	55	+32.7%
Opened positions	25	18	+38.9%
Closed positions	7	5	+40.0%
Increased positions	21	12	+75.0%
Reduced positions	15	10	+50.0%

13F shares	Current	Prev Q	Change
Total value	353.93 bn	217.10 bn	+63.0%
Total shares	10.10 mm	9.59 mm	+5.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FMR	1.52 mm	$70.01 bn	+24.3%
Mcguire Terrance	1.07 mm	$1.50 mm	0.0%
Vida Ventures II	1.03 mm	$1.44 mm	0.0%
Vida Ventures Advisors	1.03 mm	$47.49 bn	0.0%
EcoR1 Capital	849.14 k	$39.20 bn	0.0%
Farallon Capital Management	713.05 k	$32.92 bn	+37.0%
5AM Venture Management	596.66 k	$27.55 bn	-7.7%
Paradigm Biocapital Advisors	485.11 k	$22.40 bn	NEW
Vanguard	361.05 k	$16.67 bn	-18.5%
Timothy A Springer	310.22 k	$10.96 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Paradigm Biocapital Advisors	485.11 k	+485.11 k	NEW
Atlas Venture Life Science Advisors	78.45 k	-300.00 k	-79.3%
FMR	1.52 mm	+296.20 k	+24.3%
BML Capital Management	0.00	-211.75 k	EXIT
Farallon Capital Management	713.05 k	+192.65 k	+37.0%
Prosight Management	0.00	-137.61 k	EXIT
IVZ Invesco	128.18 k	+128.18 k	NEW
Ikarian Capital	142.33 k	-124.82 k	-46.7%
Susquehanna International	166.45 k	+103.70 k	+165.2%
Verition Fund Management	26.17 k	-88.61 k	-77.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TECX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Feb 25	Timothy A Springer	Common Stock	Buy	Acquire P	Yes	No	50	660,000	33.00 mm	970,223
5 Feb 25	Timothy A Springer	Common Stock	Buy	Acquire P	No	No	54.14	129,294	7.00 mm	4,226,058
5 Feb 25	Daniel Lochner	Common Stock	Buy	Acquire P	No	No	54.14	4,617	249.96 k	4,617
4 Feb 25	Peter McNamara	Common Stock	Grant	Acquire A	No	No	0	15,141	0.00	29,329
4 Feb 25	Peter McNamara	Employee Stock Option Common Stock	Grant	Acquire A	No	No	48.01	27,530	1.32 mm	27,530
4 Feb 25	Marc Schwabish	Common Stock	Grant	Acquire A	No	No	0	14,023	0.00	18,723
4 Feb 25	Marc Schwabish	Employee Stock Option Common Stock	Grant	Acquire A	No	No	48.01	25,496	1.22 mm	25,496
4 Feb 25	Daniel Lochner	Common Stock	Grant	Acquire A	No	No	0	18,074	0.00	18,074
4 Feb 25	Daniel Lochner	Employee Stock Option Common Stock	Grant	Acquire A	No	No	48.01	32,862	1.58 mm	32,862

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Tectonic Therapeutic Raises $185M in PIPE Deal, Issuing Shares at Up to $54.14 Each

Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to

Wells Fargo Maintains Overweight on Tectonic Therapeutic, Raises Price Target to $112

Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and raises the price target from $79 to $112.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Nasdaq Moves Lower; Meta Platforms Posts Strong Sales

IBM Posts Upbeat Earnings, Joins Oshkosh, Las Vegas Sands, Nokia, Quest Diagnostics And Other Big Stocks Moving Higher On Thursday

Press releases

From Benzinga Pro

Tectonic Announces $185 Million Private Placement

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced that it has entered into a securities purchase agreement for a private investment in public

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.